Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
All-Oral Anti-Viral Therapy for HCV-Related Cryoglobulinemia
NCT02825212Phase 3Completed
- Sponsor
- Icahn School of Medicine at Mount Sinai
- Start
- Feb 2016
- Primary completion
- Jul 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of ledipasvir in hepatitis C (HCV), mixed cryoglobulinemia (MC), sponsored by Icahn School of Medicine at Mount Sinai. Started Feb 2016; status: completed.
02
Drugs
ledipasvir
03
Conditions
hepatitis C (HCV)mixed cryoglobulinemia (MC)
Beyond the preview
Go deeper on NCT02825212.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02825212.